Published in J Gen Virol on July 01, 1987
The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol (1995) 2.07
A specific subform of the human cytomegalovirus transactivator protein pUL69 is contained within the tegument of virus particles. J Virol (1996) 1.74
Open reading frame UL26 of human cytomegalovirus encodes a novel tegument protein that contains a strong transcriptional activation domain. J Virol (2002) 1.57
Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol (2006) 1.40
Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol (1998) 1.34
Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication. J Virol (2002) 1.31
Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol (2006) 1.23
Human cytomegalovirus tegument proteins ppUL82 (pp71) and ppUL35 interact and cooperatively activate the major immediate-early enhancer. J Virol (2004) 1.11
Analysis of the association of the human cytomegalovirus DNA polymerase subunit UL44 with the viral DNA replication factor UL84. J Virol (2009) 1.09
Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells. J Virol (2007) 1.06
Human cytomegalovirus tegument protein ppUL35 is important for viral replication and particle formation. J Virol (2005) 0.98
Human cytomegalovirus UL44 concentrates at the periphery of replication compartments, the site of viral DNA synthesis. J Virol (2011) 0.98
Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus. Clin Exp Immunol (1991) 0.94
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine (2009) 0.94
Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein. J Virol (1999) 0.92
Procaryotic expression of phosphorylated tegument protein pp65 of human cytomegalovirus and application of recombinant peptides for immunoblot analyses. J Clin Microbiol (1990) 0.90
Human cytomegaloviruses expressing yellow fluorescent fusion proteins--characterization and use in antiviral screening. PLoS One (2010) 0.89
A faster immunofluorescence assay for tracking infection progress of human cytomegalovirus. Acta Biochim Biophys Sin (Shanghai) (2012) 0.78
Optimal replication of human cytomegalovirus correlates with endocytosis of glycoprotein gpUL132. J Virol (2010) 0.77
The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med (1992) 5.11
Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med (2001) 3.90
Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA (1986) 3.37
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00
Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr (1997) 2.93
Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology (1984) 2.91
A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods (1989) 2.53
Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J (1992) 2.40
Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol (2000) 2.36
Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol (1991) 2.16
Congenital and perinatal cytomegalovirus infections. Rev Infect Dis (1990) 2.04
Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics (1999) 1.96
Human cytomegalovirus pp28 (UL99) localizes to a cytoplasmic compartment which overlaps the endoplasmic reticulum-golgi-intermediate compartment. J Virol (2000) 1.93
Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. J Virol (1986) 1.85
Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol (1990) 1.83
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol (1997) 1.73
Detection of cytomegalovirus antibody with latex agglutination. J Clin Microbiol (1985) 1.66
Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res (1985) 1.63
Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis (1995) 1.42
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol (1989) 1.38
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente. Immunity (2001) 1.37
Human cytomegalovirus (HCMV) smallest capsid protein identified as product of short open reading frame located between HCMV UL48 and UL49. J Virol (1996) 1.35
Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol (1998) 1.34
Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics (1997) 1.33
Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol (1990) 1.33
Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr (1987) 1.30
Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol (1991) 1.28
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology (1996) 1.27
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1997) 1.24
Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol (1999) 1.23
Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol (1988) 1.21
Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol (1996) 1.20
Young children as a probable source of maternal and congenital cytomegalovirus infection. N Engl J Med (1987) 1.19
Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J Infect Dis (1983) 1.18
Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta). J Infect Dis (1998) 1.16
Evaluation of a microtiter plate fluorescent-antibody assay for rapid detection of human cytomegalovirus infection. J Clin Microbiol (1992) 1.16
Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding. J Virol (1995) 1.12
Human cytomegalovirus virion-associated protein with kinase activity. J Virol (1986) 1.11
Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol (1993) 1.10
Expression, purification, and characterization of a soluble form of human cytomegalovirus glycoprotein B. Virology (1997) 1.09
Intellectual development in school-aged children with asymptomatic congenital cytomegalovirus infection. Pediatrics (1986) 1.02
Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J Virol (1995) 1.02
Cytotoxic T lymphocyte recognition of gp70 on Friend virus-induced erythroleukemia cell clones. J Immunol (1980) 1.02
Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis (2001) 1.00
Factors associated with primary cytomegalovirus infection during pregnancy. J Med Virol (1984) 1.00
Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigens. J Clin Microbiol (1997) 0.99
Congenital and perinatal cytomegalovirus infections: clinical characteristics and pathogenic factors. Birth Defects Orig Artic Ser (1984) 0.95
Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy. Lancet (1989) 0.93
The efficacy of Doppler monitoring for the detection of venous air embolism. J Neurosurg (1981) 0.93
H-2D (Rfv-1) gene influence on recovery from Friend virus leukemia is mediated by nonleukemic cells of the spleen and bone marrow. J Exp Med (1980) 0.92
Sequence analysis and expression of the murine cytomegalovirus phosphoprotein pp50, a homolog of the human cytomegalovirus UL44 gene product. Virology (1994) 0.92
Identification of a unique erythroleukemia-associated retroviral gp70 expressed during early stages of normal erythroid differentiation. J Exp Med (1984) 0.90
B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol (2000) 0.89
Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections. J Infect Dis (1993) 0.88
Cytomegalovirus infection of human retinal tissue: an in vivo model. Lab Invest (1994) 0.87
A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology (2008) 0.86
Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis (1995) 0.85
Characterization of a membrane-associated phosphoprotein of murine cytomegalovirus (pp50) and its immunological cross-reactivity with a human cytomegalovirus protein. Virology (1991) 0.84
Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis. J Infect Dis (1995) 0.83
Antigenic and immunogenic analysis of group A and group B respiratory syncytial virus G proteins expressed from recombinant baculoviruses. J Gen Virol (1996) 0.82
Transplacentally acquired antiviral antibodies and outcome in congenital human cytomegalovirus infection. Viral Immunol (1996) 0.78
Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells. J Gen Virol (1990) 0.78
Human neural xenografts: progress in developing an in-vivo model to study human immunodeficiency virus (HIV) and human cytomegalovirus (HCMV) infection. Adv Neuroimmunol (1994) 0.78
An immunological focus assay for murine leukemia viruses on viable attached cell lines. Virology (1983) 0.78
Serological heterogeneity of CMV isolates with a monoclonal antibody. J Infect Dis (1985) 0.76
Diffuse fasciitis with eosinophilia: a steroid-responsive variant of scleroderma. J Pediatr (1980) 0.75
Tick-borne tularemia presenting as ulcerative lymphadenitis. Clin Pediatr (Phila) (1979) 0.75
Congenital cytomegalovirus infection: prospects for prevention. Ann N Y Acad Sci (1986) 0.75